Limits...
Brain Tumor Immunotherapy: What have We Learned so Far?

Van Gool SW - Front Oncol (2015)

Bottom Line: High grade glioma is a rare brain cancer, incurable in spite of modern neurosurgery, radiotherapy, and chemotherapy.We learned how to combine immunotherapy with standard multimodal treatment strategies for newly diagnosed glioblastoma multiforme patients.The developmental program allows further improvements related to newest scientific insights.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology and Immunology, KU Leuven , Leuven , Belgium.

ABSTRACT
High grade glioma is a rare brain cancer, incurable in spite of modern neurosurgery, radiotherapy, and chemotherapy. Novel approaches are in research, and immunotherapy emerges as a promising strategy. Clinical experiences with active specific immunotherapy demonstrate feasibility, safety and most importantly, but incompletely understood, prolonged long-term survival in a fraction of the patients. In relapsed patients, we developed an immunotherapy schedule and we categorized patients into clinically defined risk profiles. We learned how to combine immunotherapy with standard multimodal treatment strategies for newly diagnosed glioblastoma multiforme patients. The developmental program allows further improvements related to newest scientific insights. Finally, we developed a mode of care within academic centers to organize cell-based therapies for experimental clinical trials in a large number of patients.

No MeSH data available.


Related in: MedlinePlus

PFS and OS of adults with primary diagnosis of GBM.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4470276&req=5

Figure 4: PFS and OS of adults with primary diagnosis of GBM.

Mentions: The results of the pilot phase and the full trial phase have been published recently (27, 28). The trial was feasible without major immunotherapy-related toxicities. The integrated immunotherapy did not affect quality of life. We here present the last updated results (31 July 2014) of the PFS and OS of patients from the HGG-2006 study, divided into the EORTC RPA risk profiles three to five (Figure 4). Patient characteristics are described in Table 1. The data represent the intent-to-treat analysis. The 5-year OS for the EORTC RPA class III and class IV patients was 35.9% (asymmetrical CI95%: +25.4, −24.2) and 11.5% (asymmetrical CI95%: +10.2, −6.9), respectively. As compared to the historical control data of patients belonging to the same EORTC RPA risk profiles (4), patients from EORTC RPA class III had a better OS when immunotherapy was added to the standard treatment. These data were used to power the HGG-2010 trial.


Brain Tumor Immunotherapy: What have We Learned so Far?

Van Gool SW - Front Oncol (2015)

PFS and OS of adults with primary diagnosis of GBM.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4470276&req=5

Figure 4: PFS and OS of adults with primary diagnosis of GBM.
Mentions: The results of the pilot phase and the full trial phase have been published recently (27, 28). The trial was feasible without major immunotherapy-related toxicities. The integrated immunotherapy did not affect quality of life. We here present the last updated results (31 July 2014) of the PFS and OS of patients from the HGG-2006 study, divided into the EORTC RPA risk profiles three to five (Figure 4). Patient characteristics are described in Table 1. The data represent the intent-to-treat analysis. The 5-year OS for the EORTC RPA class III and class IV patients was 35.9% (asymmetrical CI95%: +25.4, −24.2) and 11.5% (asymmetrical CI95%: +10.2, −6.9), respectively. As compared to the historical control data of patients belonging to the same EORTC RPA risk profiles (4), patients from EORTC RPA class III had a better OS when immunotherapy was added to the standard treatment. These data were used to power the HGG-2010 trial.

Bottom Line: High grade glioma is a rare brain cancer, incurable in spite of modern neurosurgery, radiotherapy, and chemotherapy.We learned how to combine immunotherapy with standard multimodal treatment strategies for newly diagnosed glioblastoma multiforme patients.The developmental program allows further improvements related to newest scientific insights.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology and Immunology, KU Leuven , Leuven , Belgium.

ABSTRACT
High grade glioma is a rare brain cancer, incurable in spite of modern neurosurgery, radiotherapy, and chemotherapy. Novel approaches are in research, and immunotherapy emerges as a promising strategy. Clinical experiences with active specific immunotherapy demonstrate feasibility, safety and most importantly, but incompletely understood, prolonged long-term survival in a fraction of the patients. In relapsed patients, we developed an immunotherapy schedule and we categorized patients into clinically defined risk profiles. We learned how to combine immunotherapy with standard multimodal treatment strategies for newly diagnosed glioblastoma multiforme patients. The developmental program allows further improvements related to newest scientific insights. Finally, we developed a mode of care within academic centers to organize cell-based therapies for experimental clinical trials in a large number of patients.

No MeSH data available.


Related in: MedlinePlus